Healthcare professionals self-reported experiences and preferences related to direct healthcare professional communications: A survey conducted in the Netherlands

Drug Safety

Volumn 35, Issue 11, 2012, Pages 1061-1072

  Piening, Sigrid ^a   Haaijer Ruskamp, Flora M ^a   De Graeff, Pieter A ^a,b   Straus, Sabine M J M ^b,c   Mol, Peter G M ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Health care provider; Health education; Questionnaires; Risk communication.

Indexed keywords

ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; DEMOGRAPHY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENERAL PRACTITIONER; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; INTERNIST; INTERPERSONAL COMMUNICATION; NETHERLANDS; PHARMACIST; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SELF REPORT; WILCOXON SIGNED RANKS TEST;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTITUDE OF HEALTH PERSONNEL; COMMUNICATION; FEMALE; HEALTH PERSONNEL; HUMANS; MALE; NETHERLANDS; PHARMACOVIGILANCE; PRESCRIPTION DRUGS; SELF REPORT; STATISTICS AS TOPIC;

EID: 84867523367     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11635750-000000000-00000     Document Type: Review

References (28)

1. Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 07; 329 (7456): 44-7
2. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Assoc 2008 10; 300 (16): 1887-96
3. Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJ, et al. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011; 72 (3): 490-9
4. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10 (3): 211-8
5. Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12 (4): 295-301
6. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164 (9): 1356-63
7. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65 (1): 94-101
8. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007; 164 (8): 1198-205
9. European Commission. Volume 9A of the rules governing medicinal products in the European Union. Guidelines on pharmacovigilance for medicinal products for human use. 2008 Sep [online]. Available from URL: http://ec.europa. eu/health/files/eudralex/vol-9/pdf/vol9a-09-2008-en.pdf [Accessed 2012 Feb 13]
10. Slovic P. Perceived risk, trust, and democracy. Risk Anal 1993; 13 (6): 675-82
11. The European Parliament and The European Council. REGULATION (EU) No 1235/2010. 2010 [online]. Available from URL: http://eur-lex.europa.eu/ LexUriServ/Lex UriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF [Accessed 2012 Feb 13]
12. The European Parliament and The European Council. DIRECTIVE 2010/84/EU. 2010 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri= OJ:L:2010:348:0074:0099:EN:PDF [Accessed 2012 Feb 13]
13. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003 10; 362 (9391): 1225-30
14. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999 10; 282 (15): 1458-65
15. Dutch Medicines Evaluation Board. Direct Healthcare Professional Communications (DHPCS). 2012 [online]. Available from URL: http://www.cbg-meb. nl/CBG/en/human-medicines/pharmacovigilance/DHPC/default.htm [Accessed 2012 Feb 10]
16. Raosoft. Sample size calculator. 2004 [online]. Available from URL: http://www.raosoft.com/samplesize.html [Accessed 2009 Sep 17]
17. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009; (3): MR000008
18. Lee LY, Kortepeter CM, Willy ME, et al. Drug-risk communication to pharmacists: assessing the impact of riskminimization strategies on the practice of pharmacy. J Am Pharm Assoc (2003) 2008; 48 (4): 494-500
19. Health Canada. Public opinion survey on key issues pertaining to post-market surveillance of marketed health products in Canada. Health Canada, 2004 [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/pubs/medeff/ res-rec/2004-decima-2003-final-rep-rapp/index-eng.php [Accessed 2012 Feb 13]
20. Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr 2008; 29 (3): 213-5
21. Karpel JP, Peters JI, Szema AM, et al. Differences in physicians' self-reported knowledge of, attitudes toward, and responses to the black box warning on long-acting beta-agonists. Ann Allergy Asthma Immunol 2009; 103 (4): 304-10
22. Morrato EH, Curbow B, Crum RM, et al. Communicating drug risk to physicians: challenges and opportunities. Int J Risk Saf Med 2008; 20 (3): 143-54
23. Medicines and Healthcare products Regulatory Agency/Ipsos Mori. Risks and benefits of medicines and medical devices: perceptions, communication and regulation. Report on quantitative research among health professionals. 2006 [online]. Available from URL: http://www.mhra.gov.uk/Publications/Corporate/ Research/index.htm [Accessed 2012 Feb 13]
24. Berry DC. Risk, communication and health psychology. 1st ed. Berkshire: Open University Press, 2004
25. NicholsV, Theriault-Dube I, Touzin J, et al. Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada. Drug Saf 2009; 32 (7): 579-90
26. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31 (6): 525-36
27. Dutch Ministry of Health, Welfare and Sports. BIG register. Cijfers [in Dutch]. 2011 [online]. Available from URL: http://www.bigregister.nl/ overbigregister/cijfers/[Accessed 2012 Feb 7]
28. Netherlands Institute for Health Services Research (NIVEL). Beroepen in de gezondheidszorg. Databank. 2011 [online]. Available from URL: http://www.nivel.nl/data bank [Accessed 2012 May 30]